Clinical efficacy of proton magnetic resonance spectroscopy ( 1H-MRS) in the diagnosis of localized prostate cancer

Anticancer Research

Volumn 28, Issue 3 B, 2008, Pages 1899-1904

  Saito, Keisuke ^a   Kaminaga, Tatsuro ^a   Muto, Satoru ^a   Ide, Hisamitsu ^a   Nishio, Koujiro ^a   Kamiyama, Yutaka ^a   Okada, Hiroshi ^b   Terado, Yuichi ^c   Furui, Shigeru ^a   Horie, Shigeo ^a  

^a TEIKYO UNIVERSITY   (Japan)

^b DOKKYO MEDICAL UNIVERSITY   (Japan)

^c KYORIN UNIVERSITY   (Japan)

Author keywords

Accuracy of diagnosis; Prostate biopsy; Prostate cancer; Proton magnetic resonance spectroscopy

Indexed keywords

ADULT; AGED; ARTICLE; CANCER PATIENT; CLINICAL ARTICLE; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; HUMAN; HUMAN TISSUE; MALE; PREOPERATIVE PERIOD; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; PROSTATECTOMY; PROTON NUCLEAR MAGNETIC RESONANCE; SENSITIVITY AND SPECIFICITY;

AGED; BIOPSY; CHOLINE; CITRIC ACID; CREATINE; HUMANS; MAGNETIC RESONANCE SPECTROSCOPY; MALE; MIDDLE AGED; NEOPLASM STAGING; PREDICTIVE VALUE OF TESTS; PROSTATECTOMY; PROSTATIC NEOPLASMS; PROTONS;

EID: 45949104838     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (27)

1. Nakata S, Takahashi H, Ohtake N, Takei T and Yamanaka H: Trends and characteristics in prostate cancer mortality in Japan. Int J Urol 7: 254-257, 2000.
2. Presti JC Jr, O'Dowd GJ, Miller MC, Mattu R and Veltri RW: Extended peripheral zone biopsy schemes increase cancer detection rates and minimize variance in prostate-specific antigen and age-related cancer rates: results of a community multi-practice study. J Urol 169: 125-129, 2003.
3. de Jong IJ, Pruim J, Elsinga PH, Vaalburg W and Mensink HJ: 11C-Choline positron emission tomography for the evaluation after treatment of localized prostate cancer. Eur Urol 44: 32-38, 2003.
4. Rifkin MD, Zerhouni EA, Gatsonis CA, Quint LE, Paushter DM, Epstein JI, Hamper U, Walsh PC and McNeil BJ: Comparison of magnetic resonance imaging and ultrasonography in staging early prostate cancer results of a multi-institutional cooperative trial. N Engl J Med 323: 621-626, 1990.
5. Clarke DH, Banks SJ, Wiederhorn AR, Klousia JW, Lissy JM, Miller M, Able AM, Artiles C, Hindle WV, Blair DN, Houk RR and Sheridan MJ: The role of endorectal coil MRI in patient selection and treatment planning for prostate seed implants. Int J Radiat Oncol Biol Phys 52: 903-910, 2002.
6. Ikonen S, Kivisaari L, Tervahartiala P, Vehmas T, Taari K and Rannikko S: Prostatic MR imaging: Accuracy in differentiating cancer from other prostatic disorders. Acta Radiol 42: 348-354, 2001.
7. Comet-Batlle J, Vilanova-Busquets JC, Saladie-Roig JM, Gelabert-Mas A and Barcelo-Vidal C: The value of endorectal MRI in the early diagnosis of prostate cancer. Eur Urol 44: 201-207, 2003.
8. Tanaka N, Samma S, Joko M, Akiyama T, Takewa M, Kitano S and Okajima E: Diagnostic usefulness of endorectal magnetic resonance imaging with dynamic contrast-enhancement in patients with localized prostate cancer: mapping studies with biopsy specimens. Int J Urol 6: 593-599, 1999.
9. Ikonen S, Karkkainen P, Kivisaari L, Salo JO, Taari K, Vehmas T, Tervahartiala P and Rannikko S: Magnetic resonance imaging of clinically localized prostatic cancer. J Urol 59: 915-919, 1998.
10. Hricak H, White S, Vigneron D, Vigneron D, Kurhanewicz J, Kosco A, Levin D, Weiss J, Narayan P and Carroll PR: Carcinoma of the prostate gland: MR imaging with pelvic phased-array coils versus integrated endorectal-pelvic phased-array coils. Radiology 193: 703-709, 1994.
11. Costello LC and Franklin RB: Concepts of citrate production and secretion by prostate. Metabolic relationships. Prostate 18: 25-46, 1991.
12. Macara IG: Elevated phosphocholine concentration in ras-transformed NIH 3T3 cells arises from increased choline kinase activity, not from phosphatidylcholine breakdown. Mol Cell Biol 9: 325-328, 1989.
13. Thornbury JR, Ornstein DK, Choyke PL, Langlotz CP and Weinreb JC: Prostate cancer: what is the future role for imaging? AJR Am J Roentgenol 176: 17-22, 2001.
14. Scheidler J, Hricak H, Vigneron DB, Vigneron DB, Yu KK, Sokolov DL, Huang LR, Zaloudek CJ, Nelson SJ, Carroll PR and Kurhanewicz J: Prostate cancer: localization with three-dimensional proton MR spectroscopic imaging- clinicopathologic study. Radiology 213: 473-480, 1999.
15. Swindle P, McCredie S, Russell P, Himmelreich U, Khadra M, Lean C and Mountford C: Pathologic characterization of human prostate tissue with proton MR spectroscopy. Radiology 228: 144-151, 2003.
16. Kaji Y, Kurhanewicz J, Hricak H, Sokolov DL, Huang LR, Nelson SJ and Vigneron DB: Localizing prostate cancer in the presence of postbiopsy changes on MR images: role of proton MR spectroscopic imaging. Radiology 206: 785-790, 1998.
17. Japanese Urological Association and The Japanese Society of Pathology: General Rule for Clinical and Pathological Studies on Prostate Cancer (3rd edition). Pp50-56, Tokyo, Kanehara 2001.
18. Huch Boni RA, Meyenberger C, Pok Lundquist J, Trinkler F, Lutolf U and Krestin GP: Value of endorectal coil versus body coil MRI for diagnosis of recurrent pelvic malignancies. Abdom Imaging 21: 345-352, 1996.
19. Perrotti M, Han KR, Epstein RE, Kennedy EC, Rabbani F, Badani K, Pentuck AJ, Weiss RE and Cummings KB: Prospective evaluation of endorectal magnetic resonance imaging to detect tumor foci in men with prior negative prostastic biopsy: a pilot study. J Urol 162: 1314-1317, 1999.
20. Kurhanewicz J, Vigneron DB, Males RG, Swanson MG, Yu KK and Hricak H: The prostate: MR imaging and spectroscopy. Radiol Clin North Am 38: 115-138, 2000.
21. Satoh A, Matsumoto K and Nakamura S: Is interval from an initial biopsy a significant predictor of prostate cancer at repeat biopsies? Int J Urol 13: 224-227, 2006.
22. 1H-MRspectroscopy and MRimaging: clinicopatho-logic case-controlled study. Radiology 221: 380-390, 2001.
23. Prando A, Kurhanewicz J, Borges AP, Oliveira EM and Figueiredo E: Prostatic biopsy directed with endorectal MR spectroscopic imaging findings in patients with elevated prostate specific antigen levels and prior negative biopsy findings: Early experience. Radiology 236: 903-910, 2005.
24. Wefer AE, Hricak H, Vigneron DB, Vigneron DB, Coakley FV, Lu Y, Wefer J, Mueller-Lisse U, Carroll PR and Kurhanewicz J: Sextant localization of prostate cancer: comparison of sextant biopsy, magnetic resonance imaging and magnetic resonance spectroscopic imaging with step section histology. J Urol 164: 400-404, 2000.
25. Makhlouf AA, Krupski TL, Kunkle D and Theodorescu D: The effect of sampling more cores on the predictive accuracy of pathological grade and tumour distribution in the prostate biopsy. BJU Int 93: 271-274, 2004.
26. Coakley FV, Hricak H, Wefer AE, Speight JL, Kurhanewicz J and Roach M: Brachytherapy for prostate cancer: endorectal MRimaging of local treatment-related changes. Radiology 219: 817-821, 2001.
27. Jager GJ, Ruijter ET, van de kaa CA, de la Rosette JJ, Oosterhof GO, Thornbury JR, Ruijs SH and Barentsz JO: Dynamic TurboFLASH subtraction technique for contrast-enhanced MR imaging of the prostate: correlation with histopathologic results. Radiology 203: 645-652, 1997.